Navigation Links
Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis

ally fluctuate between periods of intense disease activity, during which the patient's own immune system is actively attacking and causing damage in their kidney, and periods of remission. Aspreva estimates that there are about 600,000 diagnosed lupus nephritis patients worldwide. There have been no new approved treatment options for SLE or lupus nephritis in the United States in over forty years. Current induction treatments involve the off-label use of existing cancer drugs such as cyclophosphamide, steroids, and immunosuppressants such as azathioprine. These treatments can also have life-threatening side effects that can be worse than the disease itself. Since the disease is more prevalent in women and tends to manifest itself when they are of child-bearing age, drugs that adversely affect fertility can also compound the negative impact of the disease on a patient's quality of life.

More About the Aspreva Lupus Nephritis Study

Aspreva's lupus nephritis study is one of the largest phase III studies ever conducted in lupus nephritis. This two-phase induction to maintenance study was designed as a randomized open label comparison of mycophenolate mofetil (MMF) with cyclophosphamide for the first six months (induction phase), followed by a double-blind comparison of MMF to azathioprine for up to three years (maintenance phase). Treatment response in the induction phase of this trial was defined as a decrease in proteinuria and the stabilization or improvement of serum creatinine. The first patient of this study was treated in July 2005 and patient enrollment was completed at the end of September, 2006. Re-randomization to the maintenance phase is complete and this phase of the study is ongoing. It is important to note that MMF is not currently approved by the FDA for the treatment of any autoimmune disease.

Conference Call

Aspreva will host a conference call to discuss results on Wednesday, June 27, 2007 at 9:30 a.m. ET (6:30 a.m. PT).


'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:12/1/2008)...EGO, Dec. 1 TargeGen has announced...s from a multi-center, US-based clinical,trial of...as been scheduled at,the 2008 American Society of...he presentation are as follows:, Title: ...oavailable, JAK2-Selective...
(Date:12/1/2008)...APOLIS, Dec. 1 Roche announced tod... differences in perceived pain and,discomfort ass...K blood,glucose monitoring systems and lancing de...indicated that, overall, the ACCU-CHEK Aviva and A...stems and the ACCU-CHEK Multiclix, ACCU-CHEK,Soft...
(Date:12/1/2008)...de study shows the Prox1 gene is a two-way switch ...cells to be reprogrammed so that they lose their i...ls , , MEMPHIS, Tenn., Dec. 1 /PRNewswire-U...esearch Hospital have discovered that a certain di...dentity that it requires the constant expression o...
(Date:12/1/2008)...TH MEETING, Pa., Dec. 1 ...nced that dosing of subjects has begun in study MS...se Phase 1b study of trodusquemine (MSI-1436) in o...a novel therapeutic for the treatment of type 2 di...herally to regulate insulin and leptin pathways th...
Breaking Medicine Technology:Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 2Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 3Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3Embryos Discarded During IVF Create Stem Cell Lines 10220 1Embryos Discarded During IVF Create Stem Cell Lines 10220 2Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute 10218 1Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute 10218 2Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute 10218 3The Beryl Companies Introduces New Customer Service Call Offering for Hospitals Nationwide 10216 1The Beryl Companies Introduces New Customer Service Call Offering for Hospitals Nationwide 10216 2NutraCea Provides Update on Domestic Operations 10215 1NutraCea Provides Update on Domestic Operations 10215 2NutraCea Provides Update on Domestic Operations 10215 3
...atient Lung Cancer Diversity Study, CHICAGO, June ...,lung cancer is the leading cause of cancer death ...ed to be diagnosed,and 16,700 deaths expected this...leading cause of cancer death in Hispanic men and ...ic women.(ii),Researchers at Eli Lilly and Company...
...l CBR of 52% which compares favorably with,the act..., 2007 /PRNewswire-FirstCall/ - AEterna,Zentaris I...n,endocrine therapy and oncology, today announced ...ed a poster outlining Phase 1 and,Phase 2 results ...ction inhibitor compound, for the treatment of pat...
Other Medicine Technology:Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 2Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 3Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 4Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 5Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 6Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 7Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 8Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 9Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 10Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 11AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 2AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 3AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 4
(Date:12/2/2008)...tes Healthy Habits , , NEW YORK, Dec. 2 /P...Bulletin Board: JNPC; "Juniper") Sorpresa! , Am...s network, will premiere its 60-minute live-action...max of the network,s seven-month initiative with M...M EST. , , The multifaceted program promote...
(Date:12/2/2008)... -- Neuralstem Inc.,(NYSE Alternext US: CUR) anno...ion with the China Medical University & Hospit...m,s human spinal cord neural stem cell,therapies....ral Sclerosis (ALS,or Lou Gehrig,s disease) with ...ator. , (Logo: http://www.newscom.com/cgi-...
(Date:12/2/2008)...n Medical Resources (AMR), a,provider of premier ...gnostic,imaging industries, finds that Ortho-McNe...rred quinolone antibiotic among more than half of ...ted States. Quinolone antibiotics are,used to tre...caused by,numerous bacterial pathogens. , ...
(Date:12/2/2008)...ents Will Double by 2017, According to a New Repor...., Dec. 2 Decision Resources, one ... for pharmaceutical and healthcare issues, finds t...-Cilag,s Stelara and Abbott/Eisai,s Humira, will d...to more than double to nearly $5 billion over the ...
Breaking Medicine News(10 mins):Health News:Sorpresa! Premieres Juega Como un MLS Pro 2Health News:Neuralstem Collaborates with Hospital in Taiwan to Develop Additional ALS Stem Cell Clinical Trials 2Health News:Levaquin is the Preferred Quinolone Among More Than Half of All General Medical-Surgical Hospitals in the United States 2Health News:Biologic Drugs, Particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017 2
...ormal breathing functions. Exposure to atmospheric...eart muscle during exercise in those with heart pr...ure to air pollution// with both heart disease and... the first to show how pollution can restrict the ...
...versity in Boston, a person's degree of inhibition...ies is tied to his or her likelihood of being over...--for example by choosing low-calorie foods--can h...tation to eat, according to lead investigator Dr. ...
...t common encountered among the mountaineers. Docto...rs are affected by altitude sickness and others ar...ung function may increase the risk of high altitud...e pulmonary edema (HAPE), can result when people c...
... consume wine in moderation have healthier lifesty...ther types of alcohol. It is well established tha...e health benefit,// chiefly in the form of reduced... may not be the alcohol itself, but linked lifesty...
Other Medicine News:Health News:Stop and think before you eat 2
Precision near-field imaging combined with the best handling IVUS catheter.
The Medison SonoAce 9900 is a fully digital, NT2000 based ultrasound system, with an integrated workstation that is DICOM compatible, designed for multi-specialty applications including general imagi
Full Digital Color Ultrasound
...armonic Echo technology constructs images using se...rtifacts and noise than fundamental-frequency comp...ogy to transmit distortion-free, fundamental-frequ...equency ultrasound beam is a pure sinusoidal wave,...
Medicine Products: